Logo

Pfizer’s Velsipity (etrasimod) Receives the European Commission’s Approval for the Treatment of Severely Active Ulcerative Colitis

Share this
Pfizer

Pfizer’s Velsipity (etrasimod) Receives the European Commission’s Approval for the Treatment of Severely Active Ulcerative Colitis

Shots:

  • The approval was based on the results from the P-III (ELEVATE UC 52) & (ELEVATE UC 12) clinical trials evaluating the safety & efficacy of Velsipity (2mg, QD). Velsipity received the positive CHMP opinion in Dec 2023
  • Both studies met tall the 1EPs & 2EPs by depicting a safety profile consistent with the results from previous Velsipity studies. Moreover, the study also depicted an improvement in the total IBD questionnaire score measuring the health-related quality of life
  • Velsipity is an oral S1P receptor modulator that functions by selectively binding to S1P receptor subtypes 1, 4 & 5. Earlier in Oct 2023, Velsipity received the US FDA’s approval for the treatment of adults with moderately to severely active UC

Ref: Pfizer | Image: Pfizer 

Realted Posts:-  Pfizer’s Etrasimod Receives the US FDA’s Approval for Adults with Moderately to Severely Active Ulcerative Colitis

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions